Gilead Sciences to Release Fourth Quarter & Full Year 2024 Financial Results on Tuesday, February 11, 2025
Gilead Sciences (GILD) has announced it will release its fourth quarter and full year 2024 financial results on Tuesday, February 11, 2025, after market close. The company's management will host a webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update, including 2025 guidance.
The live webcast will be accessible through the Investors section of Gilead's website and will remain archived there for one year. The biopharmaceutical company, headquartered in Foster City, California, operates in more than 35 countries and focuses on developing innovative medicines for HIV, viral hepatitis, COVID-19, and cancer.
Gilead Sciences (GILD) ha annunciato che pubblicherà i suoi risultati finanziari per il quarto trimestre e l'intero anno 2024 martedì 11 febbraio 2025, dopo la chiusura del mercato. Il management della società ospiterà un webcast alle 16:30, ora orientale, per discutere i risultati e fornire un aggiornamento aziendale, inclusi gli obiettivi per il 2025.
Il webcast in diretta sarà accessibile attraverso la sezione Investitori del sito web di Gilead e rimarrà archiviato lì per un anno. L'azienda biotecnologica, con sede a Foster City, in California, opera in più di 35 paesi e si concentra sullo sviluppo di farmaci innovativi per HIV, epatite virale, COVID-19 e cancro.
Gilead Sciences (GILD) ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año completo 2024 el martes 11 de febrero de 2025, después del cierre del mercado. La dirección de la empresa llevará a cabo un webcast a las 4:30 p.m., hora del Este, para discutir los resultados y proporcionar una actualización empresarial, incluyendo la orientación para 2025.
El webcast en vivo estará accesible a través de la sección para Inversores del sitio web de Gilead y permanecerá archivado allí durante un año. La compañía biofarmacéutica, con sede en Foster City, California, opera en más de 35 países y se enfoca en desarrollar medicamentos innovadores para el VIH, la hepatitis viral, el COVID-19 y el cáncer.
길리아드 사이언스(GILD)는 2024년 4분기 및 연간 재무 결과를 2025년 2월 11일 화요일, 시장 마감 후 발표할 것이라고 발표했습니다. 회사의 관리팀은 동부 표준시 기준 오후 4시 30분에 결과를 논의하고 2025년 가이던스를 포함한 사업 업데이트를 제공하기 위해 웹캐스트를 개최합니다.
실시간 웹캐스트는 길리아드 웹사이트의 투자자 섹션을 통해 접근할 수 있으며, 1년 동안 아카이브로 남아 있습니다. 캘리포니아 포스터 시에 본사를 둔 이 생명공학 회사는 35개국 이상에서 운영되며 HIV, 바이러스성 간염, COVID-19 및 암을 위한 혁신적인 의약품 개발에 집중하고 있습니다.
Gilead Sciences (GILD) a annoncé qu'elle publiera ses résultats financiers du quatrième trimestre et de l'année 2024 le mardi 11 février 2025, après la clôture des marchés. La direction de l'entreprise animera un webcast à 16h30, heure de l'Est, pour discuter des résultats et fournir une mise à jour sur l'entreprise, y compris les prévisions pour 2025.
Le webcast en direct sera accessible via la section Investisseurs du site Web de Gilead et y restera archivé pendant un an. L'entreprise biopharmaceutique, dont le siège est à Foster City, Californie, opère dans plus de 35 pays et se concentre sur le développement de médicaments innovants pour le VIH, l'hépatite virale, le COVID-19 et le cancer.
Gilead Sciences (GILD) hat angekündigt, dass es seine Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 am Dienstag, den 11. Februar 2025, nach Börsenschluss veröffentlichen wird. Das Management des Unternehmens wird um 16:30 Uhr Eastern Time ein Webcast veranstalten, um die Ergebnisse zu besprechen und eine Unternehmensaktualisierung zu geben, einschließlich der Prognosen für 2025.
Der Live-Webcast wird über den Investorenbereich der Gilead-Website zugänglich sein und dort ein Jahr lang archiviert bleiben. Das biopharmazeutische Unternehmen mit Sitz in Foster City, Kalifornien, ist in mehr als 35 Ländern tätig und konzentriert sich auf die Entwicklung innovativer Arzneimittel gegen HIV, Virushepatitis, COVID-19 und Krebs.
- None.
- None.
A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250128013206/en/
Jacquie Ross, CFA – Investors
investor_relations@gilead.com
Source: Gilead Sciences, Inc.
FAQ
When will Gilead Sciences (GILD) release Q4 2024 earnings?
What time is Gilead's (GILD) Q4 2024 earnings call?
Where can I access Gilead's (GILD) Q4 2024 earnings webcast?
Will Gilead (GILD) provide 2025 guidance during the Q4 2024 earnings call?
